JP6978015B1 - Composition for skin application to increase the expression of CCN1 and CCN2 - Google Patents

Composition for skin application to increase the expression of CCN1 and CCN2 Download PDF

Info

Publication number
JP6978015B1
JP6978015B1 JP2020111472A JP2020111472A JP6978015B1 JP 6978015 B1 JP6978015 B1 JP 6978015B1 JP 2020111472 A JP2020111472 A JP 2020111472A JP 2020111472 A JP2020111472 A JP 2020111472A JP 6978015 B1 JP6978015 B1 JP 6978015B1
Authority
JP
Japan
Prior art keywords
less
ccn1
ccn2
extract
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020111472A
Other languages
Japanese (ja)
Other versions
JP2022022590A (en
Inventor
徹 中西
勤 山崎
隆昭 佐伯
Original Assignee
徹 中西
勤 山崎
隆昭 佐伯
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 徹 中西, 勤 山崎, 隆昭 佐伯 filed Critical 徹 中西
Priority to JP2020111472A priority Critical patent/JP6978015B1/en
Priority to PCT/JP2021/024386 priority patent/WO2022004669A1/en
Application granted granted Critical
Publication of JP6978015B1 publication Critical patent/JP6978015B1/en
Publication of JP2022022590A publication Critical patent/JP2022022590A/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9794Liliopsida [monocotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/686Polymerase chain reaction [PCR]

Abstract

【課題】 CCN1及びCCN2の発現を増加させるための皮膚適用用の新規組成物を提供すること。【解決手段】 チョウマメの水抽出物若しくは10%未満のアルコール抽出物、及びニオイタコノキの水抽出物若しくは10%未満のアルコール抽出物のいずれか一方又は両方を含む、CCN1及びCCN2の発現を増加させるための、皮膚適用用組成物。【選択図】 なしPROBLEM TO BE SOLVED: To provide a novel composition for skin application for increasing the expression of CCN1 and CCN2. It increases the expression of CCN1 and CCN2, which comprises water extract of Clitoria ternatea or less than 10% alcohol extract and / or both of water extract of Pandan or less than 10% alcohol extract. Composition for skin application. [Selection diagram] None

Description

本開示は、CCN1及びCCN2の発現を増加させるための皮膚適用用組成物に関する。 The present disclosure relates to a composition for skin application to increase the expression of CCN1 and CCN2.

皮膚は、最表層から表皮、真皮及び皮下組織により構成される。表皮は、外的環境から身体を保護し、その健全な状態を確保する役割を担っている。表皮は、また、微生物や化学物質の侵入を抑制し、且つ水分の蒸発を防ぐことで皮膚の乾燥を防止する役割も果たす。 The skin is composed of the epidermis, the dermis and the hypodermis from the outermost layer. The epidermis plays a role in protecting the body from the external environment and ensuring its healthy condition. The epidermis also plays a role in preventing the skin from drying out by suppressing the invasion of microorganisms and chemical substances and preventing the evaporation of water.

真皮は、線維芽細胞、組織球・マクロファージ、肥満細胞、及び形質細胞から構成される。線維芽細胞は、コラーゲン、エラスチン、ヒアルロン酸などを産生する細胞であり、コラーゲンを繊維束として真皮構造を形成する役割を担っている。線維芽細胞は、また、皮膚組織に損傷が加わると損傷部に遊走し、コラーゲンなどの細胞外マトリックスの産生を開始する役割を担っている。これらの役割により、線維芽細胞は、創傷治癒の過程において重要な役割を担っている。 The dermis is composed of fibroblasts, tissue spheres / macrophages, mast cells, and plasma cells. Fibroblasts are cells that produce collagen, elastin, hyaluronic acid, etc., and play a role in forming the dermis structure with collagen as a fiber bundle. Fibroblasts also play a role in migrating to the injured area when the skin tissue is damaged and initiating the production of extracellular matrix such as collagen. Due to these roles, fibroblasts play an important role in the process of wound healing.

線維芽細胞は、さらに、紫外線、乾燥、ストレス、及び老化などの影響によって増殖能が低下する。このため、線維芽細胞の増殖能に影響があると、皮膚の弾力低下など肌の老化の原因となり、又は創傷治癒の速度が遅くなり得る。 Fibroblasts are further reduced in proliferative capacity by the effects of UV light, desiccation, stress, and aging. Therefore, if the proliferative ability of fibroblasts is affected, it may cause skin aging such as a decrease in skin elasticity, or the rate of wound healing may be slowed down.

線維芽細胞の増殖を活性化させるための研究が報告されている(特許文献1)。 Studies for activating the proliferation of fibroblasts have been reported (Patent Document 1).

特開2013−194008号公報Japanese Unexamined Patent Publication No. 2013-194008

本開示は、新規な皮膚適用用の新規組成物を提供することを目的とする。 The present disclosure is intended to provide novel compositions for novel skin applications.

本開示は、以下の発明を提供する:
[項1]
チョウマメの水抽出物若しくは10%未満のアルコール抽出物、及びニオイタコノキの水抽出物若しくは10%未満のアルコール抽出物のいずれか一方又は両方を含む、CCN1及びCCN2の発現を増加させるための、皮膚適用用組成物。
[項2]
肌の老化防止用、創傷治癒用、又は発毛促進用である、項1に記載の組成物。
[項3]
表皮幹細胞から表皮角化細胞への分化促進、或いは表皮幹細胞及び/又は表皮角化細胞の増殖促進による肌の老化防止用;線維芽細胞の増殖促進による創傷治癒用;又は毛包幹細胞から毛乳頭細胞への分化促進、或いは毛包幹細胞及び/又は毛乳頭細胞の増殖促進による発毛促進用である、項2に記載の組成物。
[項4]
チョウマメの水抽出物を含む、項1〜3のいずれか一項に記載の組成物。
[項5]
ニオイタコノキの水抽出物を含む、項1〜3のいずれか一項に記載の組成物。
[項6]
前記チョウマメの10%未満のアルコール抽出物が、チョウマメの10%未満のエタノール抽出物であり、及びニオイタコノキの10%未満のアルコール抽出物が、ニオイタコノキの10%未満のエタノール抽出物である、項1〜3のいずれか一項に記載の組成物。
The present disclosure provides the following inventions:
[Item 1]
Skin for increasing expression of CCN1 and CCN2, comprising water extract of Clitoria ternatea or less than 10% alcohol extract and / or both of water extract of Pandan or less than 10% alcohol extract. Composition for application.
[Item 2]
Item 2. The composition according to Item 1, which is used for preventing skin aging, healing wounds, or promoting hair growth.
[Item 3]
For promoting skin differentiation from epidermal stem cells to epidermal keratinocytes, or for preventing skin aging by promoting proliferation of epidermal stem cells and / or epidermal keratinocytes; for wound healing by promoting proliferation of fibroblasts; or from hair follicle stem cells to hair papillae Item 2. The composition according to Item 2, which is used for promoting hair growth by promoting differentiation into cells or promoting proliferation of hair follicle stem cells and / or hair papilla cells.
[Item 4]
Item 6. The composition according to any one of Items 1 to 3, which comprises a water extract of Clitoria ternatea.
[Item 5]
Item 6. The composition according to any one of Items 1 to 3, which comprises a water extract of Pandanaceae.
[Item 6]
Less than 10% alcohol extract of the butterfly bean is less than 10% ethanol extract of Pandan, and less than 10% alcohol extract of Pandan is less than 10% ethanol extract of Pandan. Item 2. The composition according to any one of Items 1 to 3.

水抽出物によるCCN1の発現比を示す棒グラフ。A bar graph showing the expression ratio of CCN1 by the water extract. 70%エタノール抽出物によるCCN1の発現比を示す棒グラフ。A bar graph showing the expression ratio of CCN1 with 70% ethanol extract. 水抽出物によるCCN2の発現比を示す棒グラフ。A bar graph showing the expression ratio of CCN2 by the water extract. 70%エタノール抽出物によるCCN2の発現比を示す棒グラフ。A bar graph showing the expression ratio of CCN2 with 70% ethanol extract.

「チョウマメ(Clitoria ternatea L.)」は、チョウマメ属(Clitoria)のチョウマメ属(C. ternatea)に属するマメ科の植物である。チョウマメは、例えば、公知の方法により栽培及び採取でき、又は商業的に入手可能である。1つの実施形態において、チョウマメは、花、葉、茎、及び根からなる群から選択される少なくとも1つの部位であってよく、好ましくは花、及び葉のいずれか一方又は両方であり、より好ましくは花である。チョウマメの重量は、乾燥形態の重量である。 "Clitoria ternatea L." is a leguminous plant belonging to the genus C. ternatea of the genus Clitoria. Clitoria ternatea can be cultivated and harvested, for example, by known methods, or is commercially available. In one embodiment, the Clitoria ternatea may be at least one site selected from the group consisting of flowers, leaves, stems, and roots, preferably one or both of the flowers and leaves, more preferably. Is a flower. The weight of Clitoria ternatea is the weight of the dried form.

チョウマメの水抽出物は、例えば、チョウマメの粉砕物と水とを混合し、得られた混合液から遠心分離又は濾過などの分離方法によって固形物を分離及び除去することによって得ることができる。1つの実施形態において、チョウマメ(好ましくは花の乾燥物)の水抽出物は、チョウマメの粉砕物と、前記粉砕物の10倍重量の水とを混合し、得られた混合液を室温で20分間放置した後、遠心分離又は濾過などの分離方法によって前記混合液から固形物を分離及び除去することによって得ることができる。チョウマメの水抽出物は、液体又は固体であってよい。チョウマメの水抽出物(固体)は、例えば、チョウマメの水抽出物(液体)の凍結乾燥によって調製することができる。 The water extract of Clitoria ternatea can be obtained, for example, by mixing pulverized C. elegans and water, and separating and removing the solid matter from the obtained mixture by a separation method such as centrifugation or filtration. In one embodiment, the water extract of Clitoria ternatea (preferably dried flower) is obtained by mixing the pulverized C. elegans and 10 times the weight of water of the pulverized product, and the resulting mixed solution is 20 at room temperature. It can be obtained by separating and removing the solid matter from the mixed solution by a separation method such as centrifugation or filtration after leaving it for a minute. The water extract of Clitoria ternatea may be liquid or solid. The water extract of Clitoria ternatea (solid) can be prepared, for example, by freeze-drying the water extract of Clitoria ternatea (liquid).

チョウマメの10%未満のエタノール抽出物は、例えば、チョウマメの粉砕物と10%w/w未満のエタノール水溶液とを混合し、得られた混合液から遠心分離又は濾過などの分離方法によって固形物を分離及び除去することによって得ることができる。1つの実施形態において、チョウマメの10%未満のエタノール抽出物は、チョウマメ(好ましくは花の乾燥物)の粉砕物と、前記粉砕物の10倍重量の10%w/w未満のエタノール水溶液とを混合し、得られた混合液を室温で20分間放置した後、遠心分離又は濾過などの分離方法によって前記混合液から固形物を分離及び除去することによって得ることができる。チョウマメの10%w/w未満のエタノール抽出物は、液体又は固体であってよい。チョウマメの10%w/w未満のエタノール抽出物(固体)は、例えば、チョウマメの10%w/w未満のエタノール抽出物(液体)の凍結乾燥によって調製することができる。チョウマメの10%w/w未満のエタノール抽出物(液体)は、例えば、10%w/w未満のエタノール抽出物(液体)を凍結乾燥などにより固形化して、その固形物を水で溶解した液体であってもよい。 For the ethanol extract of less than 10% of Clitoria ternatea, for example, a pulverized C. elegans and an aqueous ethanol solution of less than 10% w / w are mixed, and a solid substance is separated from the obtained mixed solution by a separation method such as centrifugation or filtration. It can be obtained by separation and removal. In one embodiment, the ethanol extract of less than 10% of Clitoria ternatea is a pulverized product of Clitoria ternatea (preferably dried flower) and an aqueous ethanol solution of less than 10% w / w, which is 10 times the weight of the pulverized product. It can be obtained by mixing and allowing the obtained mixed solution to stand at room temperature for 20 minutes, and then separating and removing solid matter from the mixed solution by a separation method such as centrifugation or filtration. The ethanol extract of less than 10% w / w of Clitoria ternatea may be liquid or solid. The ethanol extract (solid) of less than 10% w / w of Clitoria ternatea can be prepared, for example, by freeze-drying the ethanol extract (liquid) of less than 10% w / w of Clitoria ternatea. The ethanol extract (liquid) of less than 10% w / w of Clitoria ternatea is, for example, a liquid obtained by solidifying the ethanol extract (liquid) of less than 10% w / w by freeze-drying and dissolving the solid in water. May be.

チョウマメのエタノール抽出物は、例えば、8%w/w未満のエタノール、5%w/w未満のエタノール、3%w/w未満のエタノール、又は1%w/w未満のエタノールと、チョウマメの粉砕物とを混合して、得られた混合液から固形物を分離及び除去することによって調製したものであってよい。 Ethanol extract of Clitoria ternatea is, for example, ethanol of less than 8% w / w, ethanol of less than 5% w / w, ethanol of less than 3% w / w, or ethanol of less than 1% w / w, and crushed C. elegans. It may be prepared by mixing with a substance and separating and removing the solid substance from the obtained mixed solution.

「ニオイタコノキ(Pandanus)」は、タコノキ科(Pandanaceae)のタコノキ属(Pandanus)に属する単子葉植物であり、パンダリーフとも称される。ニオイタコノキは、例えば、公知の方法により栽培及び採取でき、又は商業的に入手可能である。1つの実施形態において、ニオイタコノキは、葉、茎、及び根からなる群から選択される少なくとも1つの部位であってよく、好ましくは葉、及び茎のいずれか一方又は両方であり、より好ましくは葉である。ニオイタコノキの重量は、乾燥形態の重量である。 "Pandanus" is a monocotyledonous plant belonging to the genus Pandanaceae of the Pandanaceae family, and is also called panda leaf. Pandanaceae can be cultivated and harvested, for example, by known methods, or are commercially available. In one embodiment, Pandanaceae may be at least one site selected from the group consisting of leaves, stems, and roots, preferably one or both of the leaves and stems, more preferably. It is a leaf. The weight of Pandanaceae is the weight of the dried form.

ニオイタコノキの水抽出物は、例えば、ニオイタコノキの粉砕物と水とを混合し、得られた混合液から遠心分離又は濾過などの分離方法によって固形物を分離及び除去することによって得ることができる。1つの実施形態において、ニオイタコノキ(好ましくは葉の乾燥物)の水抽出物は、ニオイタコノキの粉砕物と、前記粉砕物の10倍重量の水とを混合し、得られた混合液を室温で20分間放置した後、遠心分離又は濾過などの分離方法によって前記混合液から固形物を分離及び除去することによって得ることができる。ニオイタコノキの水抽出物は、液体又は固体であってよい。ニオイタコノキの水抽出物(固体)は、例えば、ニオイタコノキの水抽出物(液体)の凍結乾燥によって調製することができる。 The water extract of Pandanaceae can be obtained, for example, by mixing pulverized Pandanaceae with water and separating and removing the solid matter from the obtained mixed solution by a separation method such as centrifugation or filtration. .. In one embodiment, the water extract of Pandan (preferably dried leaves) is prepared by mixing a pulverized product of Pandan and 10 times the weight of water of the crushed product, and the resulting mixed solution is brought to room temperature. It can be obtained by separating and removing the solid matter from the mixed solution by a separation method such as centrifugation or filtration after leaving it for 20 minutes. The water extract of Pandanaceae may be liquid or solid. The water extract (solid) of Pandanaceae can be prepared, for example, by freeze-drying the water extract (liquid) of Pandanaceae.

ニオイタコノキの10%未満のエタノール抽出物は、例えば、ニオイタコノキの粉砕物と10%w/w未満のエタノール水溶液とを混合し、得られた混合液から遠心分離又は濾過などの分離方法によって固形物を分離及び除去することによって得ることができる。1つの実施形態において、ニオイタコノキの10%未満のエタノール抽出物は、ニオイタコノキ(好ましくは葉の乾燥物)の粉砕物と、前記粉砕物の10倍重量の10%w/w未満のエタノール水溶液とを混合し、得られた混合液を室温で20分間放置した後、遠心分離又は濾過などの分離方法によって前記混合液から固形物を分離及び除去することによって得ることができる。ニオイタコノキの10%w/w未満のエタノール抽出物は、液体又は固体であってよい。ニオイタコノキの10%w/w未満のエタノール抽出物(固体)は、例えば、ニオイタコノキの10%w/w未満のエタノール抽出物(液体)を凍結乾燥によって調製することができる。ニオイタコノキの10%w/w未満のエタノール抽出物(液体)は、例えば、10%w/w未満のエタノール抽出物(液体)を凍結乾燥などにより固形化して、その固形物を水で溶解した液体であってよい。 The ethanol extract of less than 10% of Pandanaceae is obtained by mixing, for example, a pulverized product of Pandanaceae and an aqueous ethanol solution of less than 10% w / w, and solidifying the obtained mixed solution by a separation method such as centrifugation or filtration. It can be obtained by separating and removing objects. In one embodiment, the ethanol extract of less than 10% of Pandan is a pulverized product of Pandan (preferably dried leaves) and an aqueous ethanol solution of less than 10% w / w, which is 10 times the weight of the pulverized product. It can be obtained by mixing and leaving the obtained mixed solution at room temperature for 20 minutes, and then separating and removing the solid matter from the mixed solution by a separation method such as centrifugation or filtration. The ethanol extract of Pandanaceae less than 10% w / w may be liquid or solid. An ethanol extract (solid) of less than 10% w / w of Pandanaceae can be prepared, for example, an ethanol extract (liquid) of less than 10% w / w of Pandanaceae by freeze-drying. For the ethanol extract (liquid) of less than 10% w / w of Pandan, for example, the ethanol extract (liquid) of less than 10% w / w was solidified by freeze-drying or the like, and the solid was dissolved in water. It may be a liquid.

ニオイタコノキのエタノール抽出物は、例えば、8%w/w未満のエタノール、5%w/w未満のエタノール、3%w/w未満のエタノール、又は1%w/w未満のエタノールと、ニオイタコノキの粉砕物とを混合して、得られた混合液から固形物を分離することによって調製したものであってよい。 Ethanol extracts of Pandanaceae include, for example, ethanol of less than 8% w / w, ethanol of less than 5% w / w, ethanol of less than 3% w / w, or ethanol of less than 1% w / w, and Pandanaceae. It may be prepared by mixing with the pulverized product of the above and separating the solid substance from the obtained mixed solution.

「皮膚適用用組成物」は、皮膚に適用し得る形態であればよく、溶液系、乳化系、粉末系、ゲル系、軟膏系、クリーム、ミスト、エアゾール、水−油二層系、又は水−油−粉三層系であってよい。皮膚適用用組成物は、例えば、チョウマメの水抽出物若しくは10%未満のアルコール抽出物、及びニオイタコノキの水抽出物若しくは10%未満のアルコール抽出物のいずれか一方又は両方を、前記組成物の重量当たり95%w/w以下、90%w/w以下、80%w/w以下、70%w/w以下、60%w/w以下、50%w/w以下、40%w/w以下、30%w/w以下、20%w/w以下、10%w/w以下、又は5%w/w以下含む。皮膚適用用組成物は、さらに、皮膚に適用可能な担体又は賦形剤、要すれば、適当な添加剤を適宜含んでよい。皮膚適用用組成物は、公知の方法により調製することができる。一例において、皮膚適用用組成物は、チョウマメの水抽出物若しくは10%未満のアルコール抽出物、及びニオイタコノキの水抽出物若しくは10%未満のアルコール抽出物のいずれか一方又は両方と、皮膚に適用可能な担体又は賦形剤とを混合することにより調製することができる。 The "composition for skin application" may be in a form applicable to the skin, and may be a solution system, an emulsifying system, a powder system, a gel system, an ointment system, a cream, a mist, an aerosol, a water-oil two-layer system, or water. -Oil-powder may be a three-layer system. The composition for skin application is, for example, a water extract of butterfly bean or an alcohol extract of less than 10%, and either or both of a water extract of Pandan or an alcohol extract of less than 10%. 95% w / w or less, 90% w / w or less, 80% w / w or less, 70% w / w or less, 60% w / w or less, 50% w / w or less, 40% w / w or less per weight , 30% w / w or less, 20% w / w or less, 10% w / w or less, or 5% w / w or less. The composition for skin application may further contain a carrier or excipient applicable to the skin and, if necessary, a suitable additive as appropriate. The composition for skin application can be prepared by a known method. In one example, the composition for skin application is applied to the skin with either or both of a water extract of Clitoria ternatea or an alcohol extract of less than 10% and a water extract of Pandan or an alcohol extract of less than 10%. It can be prepared by mixing with a possible carrier or excipient.

「CCN1」は、Cysteine rich 61(Cyr61)としても知られる、CCNファミリーに属するタンパク質である。CCN1は、細胞表面のインテグリン受容体及びヘパラン硫酸プロテオグリカンとの相互作用を通じて、細胞増殖、細胞運動、細胞分化、及び細胞の老化に関与する。CCN1のアミノ酸配列及び核酸配列は公知である。 "CCN1" is a protein belonging to the CCN family, also known as Cysteine rich 61 (Cyr61). CCN1 is involved in cell proliferation, cell motility, cell differentiation, and cell aging through interaction with cell surface integrin receptors and heparan sulfate proteoglycans. The amino acid sequence and nucleic acid sequence of CCN1 are known.

「CCN2」は、結合組織増殖因子(connective tissue growth factor(CTGF))としても知られる、CCNファミリーに属するタンパク質である。CCN2は、線維芽細胞の増殖促進、細胞外気質産生促進、結合組織増殖促進、軟骨細胞の増殖、細胞分化の促進、創傷治癒、及び線維性疾患に関与する。CCN2のアミノ酸配列及び核酸配列は公知である。 "CCN2" is a protein belonging to the CCN family, also known as connective tissue growth factor (CTGF). CCN2 is involved in promoting fibroblast proliferation, promoting extracellular air mass production, promoting connective tissue proliferation, chondrocyte proliferation, promoting cell differentiation, wound healing, and fibrotic diseases. The amino acid and nucleic acid sequences of CCN2 are known.

CCN1及びCCN2の「発現の増加」は、本開示に係る組成物を培養したヒトの皮膚線維芽細胞に添加した場合のCCN1の発現量及びCCN2の発現量が、本開示に係る組成物を添加しなかった場合のCCN1の発現量及びCCN2の発現量と比較して、少なくとも20%、30%、40%、又は50%増加することであってよい。CCN1及びCCN2の発現量は、CCN1又はCCN2に対応する培養したヒト線維芽細胞中のRNAの量を意味する。RNAの量は、本願明細書の実施例に記載のように、RT−PCRにより測定することができる。 The "increased expression" of CCN1 and CCN2 means that the expression level of CCN1 and the expression level of CCN2 when the composition according to the present disclosure is added to cultured human skin fibroblasts is the addition of the composition according to the present disclosure. It may be increased by at least 20%, 30%, 40%, or 50% as compared with the expression level of CCN1 and the expression level of CCN2 when not used. The expression level of CCN1 and CCN2 means the amount of RNA in cultured human fibroblasts corresponding to CCN1 or CCN2. The amount of RNA can be measured by RT-PCR as described in the examples herein.

「肌の老化防止」は、皮膚の弾力が維持される又は向上することを意味する。肌の老化防止は、CCN1及びCCN2の発現が増加し、表皮幹細胞から表皮角化細胞への分化が促進され、表皮幹細胞及び/又は表皮角化細胞の増殖が促進され、真皮幹細胞の増殖及び/又は繊維芽細胞への分化が促進され、或いは線維芽細胞の分化によるコラーゲン、エラスチン、ヒアルロン酸の産生が促進されることによって達成され得る。肌の老化防止は、例えば、本開示に係る組成物をヒトの肌に1日1回〜3回を3週間適用した場合に、本開示に係る組成物を適用しなかった場合と比べて、皮膚の弾力が維持される又は5%以上、10%以上若しくは15%以上向上することであってよい。 "Skin anti-aging" means that the elasticity of the skin is maintained or improved. To prevent skin aging, the expression of CCN1 and CCN2 is increased, the differentiation of epidermal stem cells into epidermal keratinocytes is promoted, the proliferation of epidermal stem cells and / or epidermal keratinocytes is promoted, and the proliferation of dermal stem cells and / Alternatively, it can be achieved by promoting the differentiation into fibroblasts, or by promoting the production of collagen, elastin, and hyaluronic acid by the differentiation of fibroblasts. For skin aging prevention, for example, when the composition according to the present disclosure is applied to human skin once to three times a day for 3 weeks, as compared with the case where the composition according to the present disclosure is not applied. The elasticity of the skin may be maintained or improved by 5% or more, 10% or more or 15% or more.

「創傷治癒」は、創傷治癒が促進させることを意味する。創傷治癒は、CCN1及びCCN2の発現が増加し、線維芽細胞の増殖が促進され、或いは表皮細胞が遊走及び増殖することによって達成され得る。創傷治癒は、例えば、本開示に係る組成物を皮膚の創傷に適用した場合、本開示に係る組成物を同程度の皮膚の創傷に適用しなかった場合と比べて、創傷治癒が促進されることであってよい。 "Wound healing" means that wound healing is promoted. Wound healing can be achieved by increased expression of CCN1 and CCN2, accelerated proliferation of fibroblasts, or migration and proliferation of epidermal cells. Wound healing is enhanced, for example, when the composition according to the present disclosure is applied to a wound on the skin, as compared to when the composition according to the present disclosure is not applied to a wound on the same degree of skin. It may be that.

「発毛促進」は、発毛が促進させることを意味する。毛髪促進は、CCN1及びCCN2の発現が増加し、毛包幹細胞から毛乳頭細胞への分化が促進され、或いは毛包幹細胞及び/又は毛乳頭細胞の増殖が促進されることによって達成され得る。発毛促進は、例えば、本開示に係る組成物を頭皮に適用した場合、本開示に係る組成物を適用する前と比べて、当該頭皮における毛髪が増加することであってよい。 "Promoting hair growth" means promoting hair growth. Hair promotion can be achieved by increasing the expression of CCN1 and CCN2, promoting the differentiation of hair follicle stem cells into hair papilla cells, or promoting the proliferation of hair follicle stem cells and / or hair papilla cells. The promotion of hair growth may be, for example, when the composition according to the present disclosure is applied to the scalp, the hair on the scalp is increased as compared with the case before the composition according to the present disclosure is applied.

1つの実施形態において、本開示に係る皮膚適用用組成物は、肌の老化防止、創傷治癒用、又は発毛促進用であり、好ましくは肌の老化防止又は創傷治癒用であり、より好ましくは肌の老化防止用である。 In one embodiment, the skin-applied composition according to the present disclosure is for skin aging prevention, wound healing, or hair growth promotion, preferably for skin aging prevention or wound healing, and more preferably. It is for preventing skin aging.

以下、具体的な実施例を記載するが、それらは本発明の好ましい実施形態を示すものであり、添付する特許請求の範囲に記載の発明をいかようにも限定するものではない。 Specific examples will be described below, but they show preferred embodiments of the present invention and do not limit the inventions described in the appended claims in any way.

[調製例]
以下の表に記載のNo.1〜No.8に対応する植物試料の乾燥物2gを、すり鉢とすりこぎ棒とを用いて又は袋に詰めて叩くことによって、それぞれ粉砕した。粉砕した各植物試料と水20mlと混合した。得られた混合液を20分間室温下で放置した。前記混合液を遠心分離(3000回転、10分)にかけ、上清を各植物試料の水抽出物(比較例1〜6、実施例1及び2)とした。

Figure 0006978015

[Preparation example]
No. in the table below. 1-No. 2 g of the dried plant sample corresponding to No. 8 was crushed by using a mortar and a pestle or by packing in a bag and tapping. Each crushed plant sample was mixed with 20 ml of water. The obtained mixed solution was left at room temperature for 20 minutes. The mixed solution was centrifuged (3000 rpm, 10 minutes), and the supernatant was used as an aqueous extract of each plant sample (Comparative Examples 1 to 6, Examples 1 and 2).
Figure 0006978015

以下の表に記載のNo.1〜No.8に対応する植物試料の乾燥物2gを、すり鉢とすりこぎ棒とを用いて又は袋に詰めて叩くことによって、それぞれ粉砕した。粉砕した各植物試料と70%エタノール20mlと混合した。上記と同様にして、得られた混合液から各植物試料のエタノール抽出物(比較例7〜14)を得た。

Figure 0006978015

No. in the table below. 1-No. 2 g of the dried plant sample corresponding to No. 8 was crushed by using a mortar and a pestle or by packing in a bag and tapping. Each crushed plant sample was mixed with 20 ml of 70% ethanol. In the same manner as above, ethanol extracts (Comparative Examples 7-14) of each plant sample were obtained from the obtained mixed solution.
Figure 0006978015

[細胞培養]
ヒトの皮膚線維芽細胞を、培養液3mlを含むシャーレにて培養した。前記培養液に、比較例1の水抽出物を0.25ml添加した。比較例2〜6、実施例1及び実施例2の各水抽出物0.25mlを前記培養液に添加した。対照として、水0.25mlを用いた(C1)。同様にして、前記培養液に、比較例7〜14の各エタノール抽出物0.25mlを前記培養液に添加した。対照として、70%エタノール0.25mlを用いた(C2)。前記皮膚線維芽細胞を、各抽出物が添加された培養液中、37℃、5%CO下にてさらに24時間培養した。
[Cell culture]
Human skin fibroblasts were cultured in a petri dish containing 3 ml of culture medium. 0.25 ml of the water extract of Comparative Example 1 was added to the culture broth. 0.25 ml of each water extract of Comparative Examples 2 to 6, Examples 1 and 2 was added to the culture broth. As a control, 0.25 ml of water was used (C1). Similarly, 0.25 ml of each ethanol extract of Comparative Examples 7 to 14 was added to the culture broth. As a control, 0.25 ml of 70% ethanol was used (C2). The skin fibroblasts were further cultured for 24 hours at 37 ° C. under 5% CO 2 in the culture medium to which each extract was added.

さらなる培養後に、各シャーレからヒト皮膚線維芽細胞を回収した。回収したヒト皮膚線維芽細胞におけるCCN1及びCCN2の発現量を、Applied Biosystems 7000 Sequence Detection Systemを用いたRT−PCTにより定量した。RT−PCRは、One Step TB Green(登録商標)PrimeScript(商標)RT−PCR Kitを用い、前記キットに添付の説明書に従って行った。CCN1のRT−PCRには、配列番号1及び2に記載の各核酸配列を有するプライマーを用いた。CCN2のRT−PCRには、配列番号3及び4に記載の各核酸配列を有するプライマーを用いた。 After further culture, human skin fibroblasts were harvested from each petri dish. The expression levels of CCN1 and CCN2 in the recovered human skin fibroblasts were quantified by RT-PCT using Applied Biosystems 7000 Sequence Detection System. RT-PCR was performed using the One Step TB Green® PrimeScript ™ RT-PCR Kit according to the instructions attached to the kit. For RT-PCR of CCN1, primers having each nucleic acid sequence shown in SEQ ID NOs: 1 and 2 were used. For RT-PCR of CCN2, primers having each nucleic acid sequence shown in SEQ ID NOs: 3 and 4 were used.

Figure 0006978015
Figure 0006978015

[結果]
各植物試料(No.1〜No.8)の水抽出物を用いた場合のCCN1発現量から、対照C1を用いた場合のCCN1発現量に対する相対値を算出した。算出した結果を図1に示す。図1は、植物試料No.1〜No.3、及びNo.5が、対照C1と比較して、CCN1の発現量を増加させたことを示す。
[result]
From the CCN1 expression level when the water extract of each plant sample (No. 1 to No. 8) was used, a relative value with respect to the CCN1 expression level when the control C1 was used was calculated. The calculated result is shown in FIG. FIG. 1 shows the plant sample No. 1-No. 3 and No. 5 shows that the expression level of CCN1 was increased as compared with the control C1.

各植物試料(No.1〜No.8)の70%エタノール抽出物を用いた場合のCCN1発現量から、対照C2を用いた場合のCCN1発現量に対する相対値を算出した。算出した結果を図2に示す。図2は、植物試料No.1、及びNo.3〜No.8が、対照C2と比較して、CCN1の発現量を増加させたことを示す。 From the CCN1 expression level when the 70% ethanol extract of each plant sample (No. 1 to No. 8) was used, a relative value with respect to the CCN1 expression level when the control C2 was used was calculated. The calculated result is shown in FIG. FIG. 2 shows the plant sample No. 1 and No. 3 to No. 8 shows that the expression level of CCN1 was increased as compared with the control C2.

図1及び図2は、植物試料No.1、No.3及びNo.5が、水抽出物及び70%エタノール抽出物の両方が、対照C1及びC2と比べて、CCN1の発現量をそれぞれ増加させたことを示した。図1及び図2は、また、植物試料No.2が、水抽出物の場合にはCCN1の発現を増加させるが、70%エタノール抽出物の場合はCCN1の発現を低下させることを示す。 1 and 2 show the plant sample No. 1, No. 3 and No. 5 showed that both the water extract and the 70% ethanol extract increased the expression level of CCN1 as compared to controls C1 and C2, respectively. 1 and 2 also show the plant sample No. 2 shows that in the case of a water extract, the expression of CCN1 is increased, but in the case of a 70% ethanol extract, the expression of CCN1 is decreased.

各植物試料(No.1〜No.8)の水抽出物を用いた場合のCCN2発現量から、対照C1を用いた場合のCCN2発現量に対する相対値を算出した。算出した結果を図3に示す。図3は、植物試料No.2、No.3、及びNo.8が、対照C1と比較して、CCN2の発現量を増加させたことを示す。 From the CCN2 expression level when the water extract of each plant sample (No. 1 to No. 8) was used, a relative value with respect to the CCN2 expression level when the control C1 was used was calculated. The calculated result is shown in FIG. FIG. 3 shows the plant sample No. 2. No. 3 and No. 8 shows that the expression level of CCN2 was increased as compared with the control C1.

各植物試料(No.1〜No.8)の70%エタノール抽出物を用いた場合のCCN2発現量から、対照C2を用いた場合のCCN2発現量に対する相対値を算出した。算出した結果を図4に示す。図4は、植物試料No.1が、対照C2と比較して、CCN2の発現量を増加させたことを示す。 From the CCN2 expression level when the 70% ethanol extract of each plant sample (No. 1 to No. 8) was used, a relative value with respect to the CCN2 expression level when the control C2 was used was calculated. The calculated result is shown in FIG. FIG. 4 shows the plant sample No. 1 indicates that the expression level of CCN2 was increased as compared with the control C2.

図3及び図4は、植物試料No.2、No.3及びNo.8が、水抽出物の場合にはCCN2の発現を増加させるが、70%エタノール抽出物の場合はCCN2の発現を低下させることを示す。 3 and 4 show the plant sample No. 2. No. 3 and No. 8 shows that in the case of a water extract, the expression of CCN2 is increased, but in the case of a 70% ethanol extract, the expression of CCN2 is decreased.

図1〜図4は、No.2及びNo.3の水抽出物が、対照C1及びC2と比較して、CCN1及びCCN2それぞれに発現量を増加させたことを示す。 1 to 4 show No. 2 and No. It is shown that the water extract of No. 3 increased the expression level of CCN1 and CCN2, respectively, as compared with the controls C1 and C2.

Claims (2)

チョウマメの水抽出物を含む、CCN1及びCCN2の発現を増加させるための、皮膚適用用組成物であって、前記皮膚適用用組成物が、創傷治癒用である、組成物。 A composition for skin application, comprising a water extract of Clitoria ternatea, for increasing expression of CCN1 and CCN2, wherein the composition for skin application is for wound healing. 線維芽細胞の増殖促進、或いは表皮細胞の遊走及び増殖による創傷治癒用である、請求項1に記載の組成物。 The composition according to claim 1, wherein the composition is for promoting the proliferation of fibroblasts or for wound healing by migration and proliferation of epidermal cells.
JP2020111472A 2020-06-29 2020-06-29 Composition for skin application to increase the expression of CCN1 and CCN2 Active JP6978015B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2020111472A JP6978015B1 (en) 2020-06-29 2020-06-29 Composition for skin application to increase the expression of CCN1 and CCN2
PCT/JP2021/024386 WO2022004669A1 (en) 2020-06-29 2021-06-28 Composition for application to skin to increase expression of ccn1 and ccn2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020111472A JP6978015B1 (en) 2020-06-29 2020-06-29 Composition for skin application to increase the expression of CCN1 and CCN2

Publications (2)

Publication Number Publication Date
JP6978015B1 true JP6978015B1 (en) 2021-12-08
JP2022022590A JP2022022590A (en) 2022-02-07

Family

ID=78815542

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020111472A Active JP6978015B1 (en) 2020-06-29 2020-06-29 Composition for skin application to increase the expression of CCN1 and CCN2

Country Status (2)

Country Link
JP (1) JP6978015B1 (en)
WO (1) WO2022004669A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024057970A1 (en) * 2022-09-14 2024-03-21 株式会社 資生堂 Composition comprising green tea extract, for promoting expression of ccn2

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002121110A (en) * 2000-10-12 2002-04-23 Kyoei Kagaku Kogyo Kk Cosmetic
JP2003267851A (en) * 2002-03-14 2003-09-25 Noevir Co Ltd Skin care preparation
JP2004043393A (en) * 2002-07-15 2004-02-12 Noevir Co Ltd Vascular endothelial cell growth factor production promoter
JP2004043392A (en) * 2002-07-15 2004-02-12 Noevir Co Ltd Preparation for external use for scalp and hair
JP2007016003A (en) * 2005-07-11 2007-01-25 Toyo Ink Mfg Co Ltd Antioxidant
JP2008162897A (en) * 2006-12-27 2008-07-17 Toyo Ink Mfg Co Ltd Hair care preparation
US20120269914A1 (en) * 2009-03-27 2012-10-25 Rudy Susilo Plant extracts for treating skin diseases
JP2013515054A (en) * 2009-12-22 2013-05-02 エイボン プロダクツ インコーポレーテッド Paxillin stimulating composition and its use as a cosmetic
CN108578294A (en) * 2018-06-17 2018-09-28 佛山文森特知识产权服务有限公司 A kind of skin care compositions and cosmetics promoting effect of skin-lifting and moisture-keeping efficacy

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002121110A (en) * 2000-10-12 2002-04-23 Kyoei Kagaku Kogyo Kk Cosmetic
JP2003267851A (en) * 2002-03-14 2003-09-25 Noevir Co Ltd Skin care preparation
JP2004043393A (en) * 2002-07-15 2004-02-12 Noevir Co Ltd Vascular endothelial cell growth factor production promoter
JP2004043392A (en) * 2002-07-15 2004-02-12 Noevir Co Ltd Preparation for external use for scalp and hair
JP2007016003A (en) * 2005-07-11 2007-01-25 Toyo Ink Mfg Co Ltd Antioxidant
JP2008162897A (en) * 2006-12-27 2008-07-17 Toyo Ink Mfg Co Ltd Hair care preparation
US20120269914A1 (en) * 2009-03-27 2012-10-25 Rudy Susilo Plant extracts for treating skin diseases
JP2013515054A (en) * 2009-12-22 2013-05-02 エイボン プロダクツ インコーポレーテッド Paxillin stimulating composition and its use as a cosmetic
CN108578294A (en) * 2018-06-17 2018-09-28 佛山文森特知识产权服务有限公司 A kind of skin care compositions and cosmetics promoting effect of skin-lifting and moisture-keeping efficacy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BANSEI AYURVEDA, JAPAN: "Ceylon Tea & Citron Bath & Massage Oil", MINTEL GNPD [ONLINE], JPN6020040854, November 2017 (2017-11-01), ISSN: 0004545407 *
WANDER BEAUTY, USA: "Staycation Hydrating Mask", MINTEL GNPD [ONLINE], JPN6020040851, May 2020 (2020-05-01), ISSN: 0004545406 *

Also Published As

Publication number Publication date
WO2022004669A1 (en) 2022-01-06
JP2022022590A (en) 2022-02-07

Similar Documents

Publication Publication Date Title
CN104812368B (en) Dedifferente the beautifying use of plant cell
KR100853761B1 (en) Extract of Stewartia koreana and Use Thereof
CN109152724B (en) Synergistic extract of palmaria palmiformis and jasmine, composition containing synergistic extract and application of synergistic extract
KR102294818B1 (en) Composition for skin regeneration and moisturing comprising starfish extracts
KR20110090803A (en) Cosmetic composition
KR102113645B1 (en) A cosmetic composition for preventing hair loss and promoting hair growth containing spicule powder and natural extract
KR20110119062A (en) Enriched media of human adipose tissue-derived stem cells having skin regeneration or antiwrinkle effect and uses thereof
JP6978015B1 (en) Composition for skin application to increase the expression of CCN1 and CCN2
KR101124971B1 (en) Cosmetic composition containing Salicornia herbacea callus Extracts and Laminaria digitata Extracts for Improving Skin Wrinkle or enhancing skin Elasticity
KR20100096447A (en) Cosmetic composition comprising matrials cultured adult stem cells derived from swine placenta tissue and proteins extracted therefrom
KR101798632B1 (en) Cosmetic composition containing stellera chamaejasme extract or fraction thereof and use thereof
KR101872357B1 (en) Cosmetic composition for enhancing skin elasticity containing extract of rhamnus yoshinoi
KR20170055172A (en) Cosmetic Composition Comprising Extracts of Centipeda minima
KR102509224B1 (en) Fuctional cosmetic composition
KR102369110B1 (en) Cosmetic composition containing the mixed extract of Kummerowia stipulacea and Tephroseris kirilowii
KR102508159B1 (en) Cosmetic Composition for Preventing Skin Aging and Improving Skin Winkle comprising Extract of Viburnum stellato-tomentosum
KR101679391B1 (en) Composition for treating wound containing stellera chamaejasme extract or fraction thereof and method for treating wound in a subject
KR101618726B1 (en) Method for making protein from Pollock skin
KR101597762B1 (en) Composition for treating wound containing stellera chamaejasme extract or fraction thereof and method for treating wound in a subject
KR102082676B1 (en) Composition for hair care
KR20220153271A (en) Composition for preventing forming scar comprising exosome derived from milk as an active ingredient
JP6901256B2 (en) Epithelial cell activator
KR101944494B1 (en) Cosmetic composition comprising extract of Trachelospermum species comprising Trachelospermum jasminoides as active ingredient
JP6561135B2 (en) COMPOSITION FOR TREATING Wounds, INCLUDING NUOXIN EXTRACT OR ITS FRANCIFIED AND METHOD OF TREATING Wounds of Individuals
KR102248170B1 (en) Composition for skin regeneration and wound healing comprising the extract of actinidia chinensis stem

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200811

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200811

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211026

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211102

R150 Certificate of patent or registration of utility model

Ref document number: 6978015

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117